


Technology Appraisal Committee D Interests Register Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566] Publication Date: 08/09/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	TAC Committee Member	Non-financial	The University of Leeds has received funding from Celgene and Bristol-Myers Squibb for research in an unrelated area.	15/02/2021	11/03/2021 12/05/2021	N/A	It was agreed that this declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Professor Sofia Dias	TAC Committee Member	Conflicted	Professor Dias is part of the York ERG team who carried out the assessment for this appraisal and therefore as a direct conflict Sofia did not attend the meeting for this topic.	15/02/2021 19/04/2021	15/02/2021 19/04/2021	N/A	As a direct conflict Professor Dias did not attend discussions on this appraisal.
Professor Mary O'Brien	Clinical expert	Financial	Professor O'Brien has taken part in advisory boards for the competitors MSD and Roche.	15/07/2020	11/03/2021	N/A	It was agreed that this declaration would not prevent Professor O'Brien from providing expert advice to the committee.



Dr Alastair Greystoke	Clinical expert	Financial	Dr Greystoke has previously received consultancy and speaker fees from BMS.	04/09/2020	11/03/2021	N/A	It was agreed that this declaration would not prevent Dr Greystoke from providing expert advice to the committee.
--------------------------	-----------------	-----------	--	------------	------------	-----	---